Generic Cobenfy Availability

Last updated on Jul 9, 2025.

Cobenfy is a brand name of trospium/xanomeline, approved by the FDA in the following formulation(s):

COBENFY (trospium chloride; xanomeline tartrate - capsule;oral)

• Manufacturer: BRISTOL-MYERS
  Approval date: September 26, 2024
  Strength(s): 20MG;EQ 50MG BASE ^[RLD], 20MG;EQ 100MG BASE ^[RLD], 30MG;EQ 125MG BASE ^[RLD]

Is there a generic version of Cobenfy available?

No. There is currently no therapeutically equivalent version of Cobenfy available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cobenfy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
  Patent 10,238,643
  Issued: March 26, 2019
  Inventor(s): Elenko; Eric et al.
  Assignee(s): PureTech Health LLC (Boston, MA)
  

  Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.

  Patent expiration dates:

  • July 21, 2030
    
    ✓ 
    Drug product
• Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
  Patent 10,265,311
  Issued: April 23, 2019
  Inventor(s): Elenko; Eric et al.
  Assignee(s): PureTech Health LLC (Boston, MA)
  

  Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.

  Patent expiration dates:

  • July 21, 2030
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
• Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
  Patent 10,369,143
  Issued: August 6, 2019
  Inventor(s): Elenko; Eric et al.
  Assignee(s): PureTech Health LLC (Boston, MA)
  

  Provided herein is a method of treating a central nervous system disorder in a patient in need thereof, wherein the central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia. The method comprises orally administering an initial dose of between 75 mg and 300 mg xanomeline and an initial dose of between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. Provided that the patient tolerates said administration, an increased dose of trospium chloride and an increased dose of xanomeline are orally administering to the patient, wherein the increased dose of trospium chloride is greater than the initial dose of the trospium chloride, and wherein the increased dose of xanomeline is greater than the initial dose of the xanomeline.

  Patent expiration dates:

  • July 21, 2030
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
• Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
  Patent 10,369,144
  Issued: August 6, 2019
  Inventor(s): Elenko; Eric et al.
  Assignee(s): PureTech Health LLC (Boston, MA)
  

  The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.

  Patent expiration dates:

  • July 21, 2030
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
    ✓ 
    Drug product
• Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
  Patent 10,695,339
  Issued: June 30, 2020
  Inventor(s): Elenko; Eric et al.
  Assignee(s): PureTech Health LLC (Boston, MA)
  

  The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt.

  Patent expiration dates:

  • July 21, 2030
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
• Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation
  Patent 10,925,832
  Issued: February 23, 2021
  Inventor(s): Betancourt; Aimesther et al.
  Assignee(s): Karuna Therapeutics, Inc. (Boston, MA)
  

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

  Patent expiration dates:

  • September 27, 2039
    
    ✓ 
    Drug product
• Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
  Patent 10,933,020
  Issued: March 2, 2021
  Inventor(s): Betancourt; Aimesther et al.
  Assignee(s): Karuna Therapeutics, Inc. (Boston, MA)
  

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.

  Patent expiration dates:

  • September 27, 2039
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
    ✓ 
    Drug product
• Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
  Patent 11,452,692
  Issued: September 27, 2022
  Inventor(s): Betancourt; Aimesther et al.
  Assignee(s): Karuna Therapeutics, Inc. (Boston, MA)
  

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

  Patent expiration dates:

  • September 27, 2039
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
• Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
  Patent 11,471,413
  Issued: October 18, 2022
  Inventor(s): Betancourt; Aimesther et al.
  Assignee(s): Karuna Therapeutics, Inc. (Boston, MA)
  

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

  Patent expiration dates:

  • September 27, 2039
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
• Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
  Patent 11,890,378
  Issued: February 6, 2024
  Inventor(s): Betancourt; Aimesther et al.
  Assignee(s): Karuna Therapeutics, Inc. (Boston, MA)
  

  Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

  Patent expiration dates:

  • September 27, 2039
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA IN ADULTS
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • September 26, 2029 - NEW CHEMICAL ENTITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer